Stockholm, Sweden 12/7/16; Stockholm, Sweden—AddLife, a provider of life science products for the Nordic region, has agreed to acquire Biolin Scientific from investment firm Ratos. Financial details were not released. Biolin Scientific provides analytical instruments for nanoscale material analysis and has 61 employees. For the 12-month period ending September 2016, Biolin revenues totaled SEK 100 million ($12 million = SEK 8.43  = $1), and it generated an operating EBITA of SEK 6 million ($711,000). Biolin will retain its Drug Discovery subsidiary, consisting of Sophion, which will be run as an independent company.

Ratos stated that it does not expect a significant financial gain from the divestment. Biolin Scientific products include tensiometers, Quartz Crystal Microbalance–based systems, and thin film fabrication and characterization systems. For the nine months ending September 30, Biolin Scientific sales, including Sophion, declined 13.9% to SEK 142 million ($16.9 million = SEK 8.40 = $1).